Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1150 Veterans Boulevard SOUTH SAN FRANCISCO CA 94080 |
Tel: | N/A |
Website: | https://www.nkartatx.com |
IR: | See website |
Key People | ||
Nadir Mahmood President | Paul J. Hastings Chief Executive Officer, Director | Alyssa Levin Chief Financial and Business Officer |
Ralph Brandenberger Chief Technical Officer | James Trager Chief Scientific Officer | David Shook Chief Medical Officer | Alicia J. Hager Corporate Secretary, Chief Legal Officer |
Business Overview |
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. Its NKX019 oncology program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is reliably expressed on these types of cancerous cells. Its NKX101 program is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells. |
Financial Overview |
For the nine months ended 30 September 2024, Nkarta Inc revenues was not reported. Net loss decreased 8% to $82.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.83 to -$1.31. |
Employees: | 159 as of Sep 30, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.00M as of Sep 30, 2024 |
EBITDA (TTM): | -$119.29M as of Sep 30, 2024 |
Net annual income (TTM): | -$110.61M as of Sep 30, 2024 |
Free cash flow (TTM): | -$108.41M as of Sep 30, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 70,568,754 as of Nov 4, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |